NAMS
NewAmsterdam Pharma Company N.V.- Healthcare
- Biotechnology
- $2.30B market cap
Forecast run · Oct 29, 2026Upside rank 1131 of 3,186
Model Signal
ForecastQ Daily Probabilities
32.5%
55.3%
25.8%
Analyst Consensus
Recommendation2.10/5 Buy
Last price$19.71
Price target$51.33
Implied move+160.4%
Analysts10
ForecastQ Portfolios
NAMS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.